News | November 10, 2021
Pulmatrix resolves dispute with Cipla
Cipla Technologies a subsidiary of Cipla and Pulmatrix had inked a definitive agreement for the co-development and commercialisation of Pulmazole.
Cipla Technologies a subsidiary of Cipla and Pulmatrix had inked a definitive agreement for the co-development and commercialisation of Pulmazole.
It was recognized for its holistic initiatives designed to improve the quality of life and standards of care for patients
Bioanalytical approach to accelerate development efforts in the identification of compounds that can treat chlorine or sulfur mustard injuries
Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma
A Sanofi R&D executive will join the Gyroscope Clinical Advisory Board to advise on matters related to the development of GT005 for geographic atrophy (GA).
In the overall study population through Day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo
All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO
The solution helps the pharma enterprises drive efficiencies, save costs, and increase productivity
This approval of shelf-life extension was based on the availability of additional stability data, which was submitted to CDSCO
Sputnik Light has been authorised in more than 15 countries with the registration process ongoing in a further 30 countries
Subscribe To Our Newsletter & Stay Updated
